Gründer G, Mertens L, Jungaberle A, Jungaberle H, Spangemacher M. Compassionate use of psilocybin for treatment-resistant depression in Germany. Lancet Psychiatry. 2026 13(2):91-93. Epub 2025 Sep 18.
Mertens L, Koslowski M, Betzler F, Brand M, Evens R, Kärtner L, Jungaberle A, Jungaberle H, Majic T, Schmitz C, Ströhle A, Scharf D, Spangemacher M, Wolff M, Assadi Z, Bahri S, Becher L, Färber LV, Kirchen N, Kulakova E, Kunz L, Meijer A, Rohrmoser B, Wellek S, Berger M, Gründer G. Efficacy and Safety of Psilocybin in Treatment-Resistant Major Depression: The EPISODE Randomized Clinical Trial. JAMA Psychiatry. 2026 Mar 18. [Epub ahead of print]
Mlynek E, Tan X, Lammertz SE, Schaffrath S, Gründer G, Schneider F, Frodl T, Mathiak K, Gaebler AJ. Disturbed Functional Connectivity Between Anterior Default Mode and Sensory Processing Regions Is Linked to Peripheral Inflammatory Markers and Psychopathology in Schizophrenia. Schizophr Bull. 2026 52(1):sbaf048. Epub 2025 Apr 23.
Schmidt M, Hoffrichter A, Davoudi M, Horschitz S, Lau T, Meinhardt M, Spanagel R, Ladewig J, Köhr G, Koch P. Psilocin fosters neuroplasticity in iPSC-derived human cortical neurons. Elife. 2026 14
Spangemacher M, Reinwald J, Karl S, Sartorius A. Rethinking Seizure Termination: A Possible Paradigm Shift in Understanding a Primary Mechanism of ECT. J ECT. 2026 Mar 4. [Epub ahead of print]